Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Positive Two-Year Data Boost Prospects For Vivus' Qnexa

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Two-year Qnexa data released by Vivus Sept. 21 could serve to bolster the long-term prospects for the weight-loss drug as they address areas of concern identified during recent reviews of obesity drugs by FDA's Endocrinologic and Metabolic Drugs Advisory Committee - including higher efficacy standards and the need to show benefit on co-morbidities associated with weight loss

You may also be interested in...



FDA Pressed At Meridia Committee Review To Finalize Obesity Drug Guidance

FDA is facing strong pressure from its own advisory committee members to finalize development standards for weight-loss drugs.

Arena Must Deal With Rat Neoplasms To Move Forward With Lorqess

A major task confronting Arena as it pursues approval of Lorqess is to provide FDA with an explanation that shows the neoplasms found in rats during animal studies of the obesity drug are not a predictor of cancer risk in humans.

Qnexa May Get Staged Launch After No Vote From Advisory Committee

Safety concerns and a large market potential for Vivus's obesity drug combine to produce an advisory panel recommendation that leaves FDA "a little surprised."

Related Content

Topics

UsernamePublicRestriction

Register

PS004563

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel